1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
  2. Dear Guest, we realise advertising is annoying, it is however necessary to help us be a sustainable resource for all, if you want to go advert free then please use the following link to subscribe for £5 a month: Click here
    Dismiss Notice

(HIK) Hikma Pharmaceuticals General Share Chat

Discussion in 'General Share Chat' started by Microem1, Nov 6, 2015.

  1. Microem1

    Microem1 Administrator

    Messages:
    89
    Reputation:
    0
    (HIK) Hikma Pharmaceuticals General Share Chat
     
  2. Mongoose82

    Mongoose82 A Legendary Member

    Messages:
    977
    Reputation:
    40
    "The past year has been a turbulent one for Hikma. A shortage-fuelled growth spurt and a resulting guidance upgrade had heralded the Jordanian company’s entry into the FTSE 100 in March 2015 (following the c.25% rally since the beginning of the year), making it only the fourth pharma constituent to become a component of this ‘blue-chip’ index. Fast forward a year, however, and multiple downgrades later, investor enthusiasm towards the company had waned, resulting in the stock being kicked out of the index in March 2016." AlphaValue's view: https://www.research-tree.com/company/GB00B0LCW083
     

Share This Page